Key Takeaways
- • Private credit firms including PSP Investments, Oaktree Capital Management, Franklin Templeton, Palmer Square Capital Management, Oak Hill Advisors, Sona Asset Management, Lord Abbett, and Blackstone's own credit arm have committed approximately $2 billion to the second-lien tranche of Blackstone and TPG's Hologic acquisition, demonstrating private credit's growing centrality in large-scale sponsor-backed transactions.
- • The subordinated debt layer is priced at 5 percentage points over the floating benchmark and was issued at 99 cents on the dollar, offering higher yields in exchange for increased subordination risk—a trade-off reflecting current private credit market dynamics and investor appetite for elevated returns.
- • The total financing package for the $18.3 billion Hologic acquisition reaches $12.25 billion, with the senior portions ($9.5 billion) expected to syndicate as early as January 2026, indicating robust banking and institutional capital availability for marquee transactions.
- • Blackstone and TPG retained control over sourcing the subordinated debt investors themselves, bypassing traditional bank fee capture and demonstrating sponsor influence over capital stack composition in large transactions, a shift in deal dynamics favoring direct sponsor-lender relationships.
- • Abu Dhabi Investment Authority and Singapore's GIC are also acquiring minority stakes in Hologic alongside the debt financing, signaling institutional investor confidence in the women's health medical device and diagnostics sector.
Summary
Private credit has solidified its role as a critical capital provider in large-scale leveraged buyouts, with a consortium of alternative asset managers committing $2 billion to the second-lien debt tranche backing Blackstone and TPG's acquisition of Hologic. The subordinated debt, priced at 5 percentage points over the floating benchmark and issued at par (99 cents on the dollar), represents the riskier, higher-yielding portion of the deal's $12.25 billion total financing package.
The debt syndication underscores a structural shift in sponsor-led acquisition financing. Rather than allowing lead arrangers—Citigroup, Barclays, RBC Capital Markets, and Bank of America—to exclusively syndicate subordinated tranches, Blackstone and TPG directly sourced the $2 billion second-lien allocation themselves. This approach reduced traditional bank fee revenue while strengthening sponsor control over capital stack composition and lender composition. The move reflects the maturation of alternative credit markets and sponsors' confidence in their own distribution capabilities.
The investor consortium spans established credit platforms and institutional allocators. PSP Investments, Canada's pension fund manager, joined Oaktree Capital Management, Franklin Templeton, Palmer Square Capital Management, Oak Hill Advisors, Sona Asset Management, and Lord Abbett. Notably, Blackstone deployed its own credit arm into the deal, aligning internal capital with the transaction thesis. This syndication pattern mirrors recent marquee transactions including CapVest's financing for Stada and Sycamore Partners' take-private of Walgreens Boots Alliance, indicating institutionalization of private credit's role in sponsor-backed M&A.
The broader financing package reflects confidence in the women's health diagnostics sector. Blackstone and TPG's $18.3 billion acquisition price for Hologic—reached last month—includes provisions for up to that valuation ceiling. Abu Dhabi Investment Authority and Singapore's GIC are acquiring minority stakes alongside the debt financing, signaling heavyweight institutional co-investment. The senior tranche of approximately $9.5 billion is expected to syndicate in early January, likely to institutional credit investors and traditional bank portfolios.
This transaction exemplifies how private credit has become structurally embedded in sponsor-backed financing, with direct lenders and credit funds now routinely absorbing subordinated risk layers at scale. The $2 billion second-lien commitment reflects both strong institutional appetite for yield and sponsors' demonstrated ability to access capital independent of traditional banking intermediaries on marquee deals.
The debt syndication underscores a structural shift in sponsor-led acquisition financing. Rather than allowing lead arrangers—Citigroup, Barclays, RBC Capital Markets, and Bank of America—to exclusively syndicate subordinated tranches, Blackstone and TPG directly sourced the $2 billion second-lien allocation themselves. This approach reduced traditional bank fee revenue while strengthening sponsor control over capital stack composition and lender composition. The move reflects the maturation of alternative credit markets and sponsors' confidence in their own distribution capabilities.
The investor consortium spans established credit platforms and institutional allocators. PSP Investments, Canada's pension fund manager, joined Oaktree Capital Management, Franklin Templeton, Palmer Square Capital Management, Oak Hill Advisors, Sona Asset Management, and Lord Abbett. Notably, Blackstone deployed its own credit arm into the deal, aligning internal capital with the transaction thesis. This syndication pattern mirrors recent marquee transactions including CapVest's financing for Stada and Sycamore Partners' take-private of Walgreens Boots Alliance, indicating institutionalization of private credit's role in sponsor-backed M&A.
The broader financing package reflects confidence in the women's health diagnostics sector. Blackstone and TPG's $18.3 billion acquisition price for Hologic—reached last month—includes provisions for up to that valuation ceiling. Abu Dhabi Investment Authority and Singapore's GIC are acquiring minority stakes alongside the debt financing, signaling heavyweight institutional co-investment. The senior tranche of approximately $9.5 billion is expected to syndicate in early January, likely to institutional credit investors and traditional bank portfolios.
This transaction exemplifies how private credit has become structurally embedded in sponsor-backed financing, with direct lenders and credit funds now routinely absorbing subordinated risk layers at scale. The $2 billion second-lien commitment reflects both strong institutional appetite for yield and sponsors' demonstrated ability to access capital independent of traditional banking intermediaries on marquee deals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.